



R&D Contact: John Garner
Location: West Lafayette, IN
Email: jg@akinainc.com
Tel: 765-464-0501x6#
Website: <http://www.akinainc.com/index.html>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health



National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Overview

Industry Sector: Drug Delivery/Medical Device/Research Products
Specialty in biodegradable polymer based products and quick dissolve tablets

Company Overview:

Akina Inc. is a revenue generating biopharmaceutical company founded in 2001 by professor and drug delivery and device expert, Kinam Park at Purdue University. Akina develops new drug delivery/device technologies. Current innovations are in the areas of fast-melting tablets, biodegradable polymer based implants. Akina also provides research products, such as fluorescent probes. The fast-melting tablet technology is currently in use for delivery of nutraceuticals. Akina's delayed hydrogel tissue expander is a research-stage biomedical device for use in dental procedures (e.g., gum line expansion).

Target Market(s): Frosta Nutraceuticals -Direct consumers; Research Products – Research companies and universities; Restiex/Bisourest – Periodontal Surgeons / Hospitals and healthcare providers world wide, respectively

Seeking: Strategic Partner (Restiex) and Distribution Partners (Drug Delivery)

Key Value Drivers

Technology*:

Restiex™ is the first of its kind reshapable, self-filling, tissue expander intended to aid in surgical implantation of a prosthetic device in the jaw or dental area.

Bisourest™ is a biodegradable ureteral stent which eliminates the need for a secondary removal surgery from the ureter thus saving time and money.

Nanoparticle Technology Akina is currently developing a novel nanofabrication technology which can allow for the generation of nanoparticles which are uniform in size and have high drug loading.

Frosta™ Technology is the premier method of formulating fast melting tablets with conventional granulating and tableting equipment; eliminating the need for expensive processes and equipment.

Competitive Advantage: Only Restiex is reshapable, self-filling, and expandable.

Feature	Restiex	Osmed	Silicone
Reshapable	X		
Self-filling	X	X	
Expandable	X	X	X

Strategy: Akina is seeking partners for working towards clinical development of our implantable technology.

Management

Management Team has over 80 combined years of experience in research and development.

Leadership:

Kinam Park (President)
 Haesun Park (Vice President)
 John Garner (Manager)
 Yourong Fu (Director of Formulations)
 Sarah Skidmore (Formulations Scientist)

Scientific Advisory Board:

Clark T. Barco, PhD, Director of Periodontics at Roudebush VA Medical Hospital
 Nathan Blumberg, MD, Retired Urologist
 Larry G. Adams, DVM, PhD, Professor of Veterinary Clinical Sciences of Purdue University

Product Pipeline

	In-vitro	Animal	Clinical	Commercial
Restiex Tissue Expander				
Bisourest Ureteral Stent				
Frosta Quick Dissolve Tablets				
Nanoparticle Fabrication Technology				
				Research Products